CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS

这项提案的目标是在堪萨斯州建立一个“癌症实验治疗中心”。三所州立机构联合其资源和师资，建立了一个中心，指导初级教师进行癌症相关研究，并为化学和生物学界面的实验提供新的基础设施。由堪萨斯大学（KU）和堪萨斯技术企业公司（KTEC）提供的配套资金以及NIH-COBRE的支持将建立独特的核心设施，以确定新的生物活性化合物，这些化合物将成为有用的基础生物医学研究工具和潜在的治疗剂。堪萨斯大学在药物化学方面有着强大的传统，与未来五年基础生物医学研究初级教师的扩张和更替的关系，使堪萨斯大学成为建立实验治疗研究中心的合理地点。基金被要求支持五个项目，其中初级教师和一位成功的高级教师以前没有得到NIH的资助，作为私人顾问。这些教师与未来新兵的竞争力合作，并将建立一个获得大型设备和设施支持的竞争性计划。Two Cores将由一组经验丰富的研究人员建立和运营，他们在组合化学、细胞和分子生物学、生物化学、癌细胞生物学以及开发用于化合物和细胞靶标识别的新型生物测定等领域具有专业知识。新化合物的生成和分析的专业知识，以及用于筛选的生物测定的开发的专业知识的结合，为将两个研究领域联合起来提供了一个独特的机会。这些核心将与新的初级教员合作，筛选来自国家癌症研究所知识库的化合物库，来自商业来源的化合物库，以及现场生成的化合物库，以确定能够增强他们研究的试剂。

The goal of this proposal is to establish a "Center for Cancer Experimental Therapeutics" in the State of Kansas. Three state institutions combine their resources and faculty to establish a Center to mentor junior faculty in cancer-related research and novel infrastructure needed for experimentation at the interface between chemistry and biology. Matching funds provided by the University of Kansas (KU) and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE support will result in the establishment of unique core facilities needed to identify novel bioactive compounds that will be useful basic biomedical research tools, and potential therapeutic agents. A strong tradition in medicinal chemistry at KU, relationships with expansion and turnover of junior faculty in basic-biomedical research over the next five years makes Kansas a logical site for establishing a Center for research in experimental therapeutics. Funds are requested for the support of five projects in which junior faculty and one successful senior faculty not previously funded by NIH serve as P.I.s. These faculty are partnered with competitiveness of future recruits, and a competitive program for the obtainment of large-scale equipment and facilities support will be established. Two Cores will be established and operated by an experienced group of investigators with expertise in the areas of combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for joining two research areas into two combined effort. The Cores will work with new junior faculty to screen compound libraries from the National Cancer Institute repositories, those from commercial sources, and those generated on-site, for identification of reagents that will enhance their research.